This metabolite has a PDE selectivity profile just like sildenafil and an in vitro potency for PDE5 around 50% from the guardian drug. Plasma concentrations of this metabolite are around forty% of Individuals noticed for sildenafil, so that the metabolite accounts for around 20% of sildenafil's pharmacologic outcomes.In Individuals patients by now